Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by frebeach1on Feb 17, 2023 11:54pm
205 Views
Post# 35293336

RE:Treatment Cost

RE:Treatment CostWay back at the time when they were testing with mice, the charging expectation was $50,000 per Canadian patient and not charging so much to be only a remedy for the richest people, assuming we kept this technology access for all Canadians regardless of whether they are rich or poor.

Dave at Bare Oaks. Canada.

Camphikefish wrote: Hi everyone, I read today that Alstiladrin treatment is expected to fall roughly between 160k and 260k per patient. 80,000 new cases per year in the US makes it a total opportunity of 1.2 billion using 160k as a multiplier. 25% of that is a realistic 300 million in sales revenue and a fair target number for 1433. Does anyone know the math from here? In orthopedics the somewhat historical buyout number has been 6 X annual sales give or take. These are US numbers alone so we could be worth 1.8 billion easily however, I realize we all believe we're worth far more. Wonder what we would be worth with worldwide numbers included? Curious again what others believe we will be bought for just for fun. 


<< Previous
Bullboard Posts
Next >>